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Case presentations
Patient 1. A 33-year-old woman was admitted to St. Paul's Hospital
in Vancouver, B.C. with cramps in her hands and feet. An intestinal
bypass operation had been performed 4 years earlier because of obesity
(her weight was 122.5 kg prior to operation). A cholecystectomy had
been performed at the same time. Over the next 2 years she lost 61.2 kg
and was well except for episodic diarrhea. One year prior to the present
admission, she had been admitted to the hospital; the serum magnesium
was 0.56 mEq/liter and calcium was 6.6 mg/dl. Serum magnesium was
corrected over 24 hours with magnesium sulfate to 2.16 mEq/liter, and
the serum calcium level rose spontaneously to 8.2 mg/dl over 3 days.
A few weeks prior to the present admission, her bowel movements
increased to 20 to 30 per day, and she noticed progressive weakness,
cramps in her hands, and circumoral numbness. On admission, blood
pressure was 130/90 mm Hg; pulse rate was 80 lying and standing. The
only abnormal physical finding was a positive Chvostek's sign. Labora-
tory results were as follows: sodium, 144 mEq/liter; potassium, 3.1
mEq/liter; chloride, 109 mEq/liter; total C02, 29 mmol/liter; BUN, 7
mg/dl; serum creatinine, 0.7 mg/dl; calcium, 6 mg/dl (normal, 8.6—10.3);
magnesium, 0.4 mEq/liter (normal, 1.4—2. 10); total protein, 5.6 g/dl; and
serum albumin, 3.3 g/dl. Hemoglobin was II g/dl. Serum vitamin B1,,
serum folate, and serum parathyroid hormone were normal. Results of
urinalysis were normal. A spot urine magnesium concentration was 0.5
mEq/liter. Electrocardiogram was normal, including the QT interval.
Because of marked hypomagnesemia, hypocalcemia, and tetany, the
patient was given 8 mEq of magnesium as 50% magnesium sulfate
hourly for 6 hours and then 8 mEq every 4 hours; she also received 25
mEq of potassium chloride twice daily. Serum magnesium rose to 0.96
mEq/liter within 3 hours and to 3.6 mEq/liter after 11 hours. She was
given 500mg of calcium salts three times daily, and the plasma calcium
rose to 8.6 mg/dl. Potassium rose to 3.5 mEq/liter. All signs and
symptoms of hypomagnesemia and hypocalcemia disappeared and
remained absent while she received 48 mEq of magnesium per day. The
24-hour urinary magnesium excretion rose to 42 to 50 mEq/Iiter; this
value reflects a fractional urinary magnesium excretion of 28% to 42%.
Patient 2. A 36-year-old woman was hospitalized at Vancouver
General Hospital because of lower abdominal distension. The only
previous medical problem was hyperthyroidism. She had been treated
with 131J one year prior to admission and was maintained on replace-
ment therapy with I-thyroxine. On admission, pelvic examination
disclosed bilateral ovarian masses; a subsequent laparotomy revealed
bilateral ovarian papillary cystadenomas with small omental and hepat-
ic metastases. Hysterectomy and bilateral salpingo-oophorectomy were
performed. She was treated with seven cycles of melphalan over 8
months; a second laparotomy disclosed no remaining tumor. Subse-
quently she was given eight cycles of doxorubicin and cisplatin, a total
of 625mg of each drug, for 7 months. A third laparotomy disclosed a I
cm lesion on the anterior wall of the sigmoid colon and a 0.4 cm nodule
in the right paracolic gutter. The tumor was a poorly differentiated
adenocarcinoma, presumably a metastasis from the original lesion. The
patient was given a course of radiotherapy.
She was readmitted to the hospital 20 months later with a 2-week
history of malaise, fatigue, bruising, dyspnea on exertion, and hemato-
chezia. Hemoglobin was 6 g/dl; platelet count was 15,000/mm3; and she
had 20% blast cells on peripheral smear. Bone-marrow biopsy showed
acute nonlymphocytic leukemia with 82% blast cells. Chromosomal
analysis revealed a pattern not previously reported in humans. She was
diagnosed as having chemotherapy-induced leukemia, and drug therapy
was begun; she also received a bone-marrow transplant from an
identical twin with complete HLA, red cell genotype, and mixed-
lymphocyte culture compatibility.
A low serum magnesium concentration (1.2 mEq/liter; normal range,
1.8—2.8 mEq/liter) was documented for the first time just prior to bone-
marrow transplantation. Serum calcium was 9.6 mg/dI; phosphate, 4.1
mg/dl; total protein, 6.3; and albumin, 2.7 g/dl. Preparation for bone-
marrow transplantation included treatment with methotrexate, cyclo-
phosphamide with concurrent furosemide diuresis, and bladder irriga-
tion. She also received tobramycin, carbenicillin, and radiotherapy.
Serum magnesium fell to 0.6 mg/dl, and she required continuous
magnesium supplementation over the next several weeks. Following
bone-marrow transplantation, she developed pseudomonas septicemia,
which was treated with amikacin, piperacillin, and cefazolin. She also
developed candida septicemia requiring treatment with 1.2 g of ampho-
tericin B. Hypomagnesemia persisted and hypokalemia developed.
Hemolytic anemia became apparent, and bone-marrow aspiration re-
vealed hypocellular marrow. At discharge, the patient was given
prednisone, potassium supplements, and 15 ml of magnesium glucohep-
tonate thrice daily (225 mg of elemental magnesium per day).
Two months later, weakness, fatigue, dizziness on standing, and
dyspnea on exertion prompted her readmission to the hospital. She had
decreased appetite and increased thirst. Physical examination revealed
a pale 40-year-old woman with marked oral candidiasis, but otherwise
physical examination was normal. The hemoglobin was 4.6 g/dl. Serum
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hemoglobin was 53 mg/dl; haptoglohin, 10 mg/dI: serum sodium. 136
mEq/liter; potassium. 2.9 mEq/liter; chloride. 105 mhq/liter: bicarbon-
ate, 23 mEq/liter; magnesium, 0.4 mg/dl; and albumin. 3.4 g/dl. Predni-
sone was increased to 100 mg daily and the patient was transfused with
4 Units of packed cells. The administration of 10 g of magnesium sulfate
intravenously over the next 16 hours resulted in an increase in serum
magnesium to 1.2 mg/dl. Hemoglobin stabilized at It) g/dI. The dietary
magnesium intake of 250 to 300 mg/day was supplemented with 75 ml of
magnesium glucoheptonate H75 ing of elemental magnesium per day).
Prior to the patient's discharge, the serum calcium was 8.8 mg/dI:
magnesium, 0.8 mg/dl; phosphate. 3.7 mg/dl: serum creatinine. 0.8
mg/dl; potassium. 4.0 mEq/liter; and hemoglobin. 10 g/dl. Twenty-four
hour urinary magnesium excretion 120 mg; of
calcium, 185 mg; and of potassium, 60 mEq. The creatinine clearance
was 65 mI/mm and the fractional magnesitim excretion was 29.2%;
fractional calcium and potassium excretions were 0.5% and 27.6%.
respectively. Two weeks later, serum magnesium. potassium, calcium,
and hemoglobin levels were stable.
Discussion
DR. JOHN H. DIRKS (Proftssor and Head, Department of
Medicine, University of British Columbia and Vancouver Gen-
eral Hospital, Vancouver, B.C., Canada): These 2 patients
presented with complicated histories but both had profound,
symptomatic hypomagnesemia requiring treatment with magne-
sium salts. Two different mechanisms for hypomagnesemia are
illustrated. The first patient's low serum magnesium was due to
gastrointestinal malabsorption and marked diarrhea. The great-
ly reduced serum magnesium and serum calcium levels resulted
in all the clinical hallmarks of neuromuscular irritability such as
earpopedal spasm and Chvostek's sign. The kidney in this
patient responded appropriately to hypomagnesemia and con-
served magnesium maximally, in contrast, the hypomagnese-
mia in the second patient was due to a persistent renal magne-
sium leak; she had concomitant hypocalcemia and hypokale-
mia. These two patients provide the backdrop for out
discussion of the role of the kidney in normal magnesium
homeostasis and the relationship of magnesium to calcium and
potassium metabolism. I will return to these two patients after
disctissing normal and abnormal renal magnesium handling.
Normal renal handling of /nagnesium
Magnesium has been the l'orgotten cation. It is the foui'th
most abundant cation in the body and the second most abun
dant (after potassium) in the cells. Total-body magnesitim is
approximately 24 g: hone and skeletal muscle are the major
reservoirs for magnesium, containing 60% and 20% respective-
ly, hut most cellular magnesium is not readily exchangeable.
Serum magnesium is carefully regulated between 1.4 and 2.1
mEq/liter ((1.7—1.0 mM or 1.7—2.3 mg/dl). Normally we ingest
approximately 300 mg (25 mEq) of magnesium per day, and
about one-third of the intake is absorbed by the gastrointestinal
tract. Renal magnesium handling is essentially a filtration-
reabsorption process even though magnesium secretion has
been suggested [1, 2]. The data supporting magnesium secretion
still are not compelling, and if magnesium secretion occurs it
contributes only in a minor way to overall magnesium balance.
Eighty percent of the serum magnesium is ultrafilterable (of
which 70% to 80% is ionized). Over a 24-hour period, 3500 mg
of magnesium is filtered; in humans only about 3% of this
amount is excreted in the urine, or approximately 100 to 150
mg/day (8—15 mEq/day). an amount equal to that absorbed by
the gastrointestinal tract each day.
Micropuncture studies have disclosed considerable informa-
tion about magnesium reabsorption in the various nephron
segments [3]. In the proximal tubule, the magnesium concentra-
tion rises along the length of the ttibule and attains a value 1.5
times that in an ultrafiltrate of plasma [4]. This is unlike sodium
or calcium: sodium concentiation in the proximal tubule is
essentially identical to an ultrafiltrate of plasma: the calcium
concentration rises only 10% to 20% above that in the ultrafil-
trate. The high tubular fluid/ultrafiltrate (TF/UF) magnesium in
the proximal tubule remains unaltered despite changes in plas-
ma magnesium and calcium. The high concentration of magne-
sium in the proximal tubule fluid reflects the very low perme-
ability of the proximal tubule epithelium to magnesium. Magne-
sium reabsorption in the proximal tubule is largely a
unidirectional process, and the rate of reabsorption is directly
related to the concentration of magnesium in the luminal fluid.
The proximal tubular reabsorption of magnesium is only 25% to
30% of the filtered load, in contrast to 50% to 60% of the filtered
load for sodium and water (accounting for the TF/UF magne-
sium of 1.5). However, overall absolute reabsorption of magne-
sium is proportional to proximal sodium and water reabsorp-
tion. Details of the cellular process of reabsorption of magne-
sium in the proximal tubule remain largely unknown.
Magnesium concentration continues to rise as the tubular
fluid traverses the descending limb of Henle's loop and can
reach a concentration three- to fourfold that of the plasma
ultrafiltrate [5, 61. Thus, relatively higher concentrations of
magnesium (compared to plasma ultrafiltrate) enter the ascend-
ing limb than of other ions.
The thick ascending limb of Henle's loop is now known to be
the major site of magnesium reabsorption in the renal tubule
and the principal locus of renal control of magnesium excretion.
LeGrimellec, Roinel, and Morel observed in 1973 that magne-
sium concentration in the early distal tubule fluid was well
below the plasma ultrafiltrate [41. Distal tubular fluid to ultrafil-
trate magnesium concentration ratios were calculated at ap-
proximately 0.6. Coupled with the marked water reabsorption
that takes place before this site in the nephron. a TF/UF
magnesium ratio of 0.6 indicates that 50% to 60% of the filtered
magnesium is reabsorhed between the thin descending limb and
the early distal tubule, a fractional reabsorption much greater
than that of sodium or calcium. The thick ascending limb of
Henle's loop appears to be the segment responsible for the hulk
of the observed magnesium reabsorption.
Recent in-vitro microperfusion studies confirm that net mag-
nesium reabsorption does take place in the thick ascending limb
of Henle's loop and is voltage dependent [7]. Such microperfu-
sion studies have given us considerable knowledge of the
characteristics ol' the reabsorption of magnesium in the thick
ascending limb of the loop of Henle 8]. We observed that when
the luminal concentration of magnesium was elevated piogres-
sively, the loop of Henle reabsorbed progressively more magne-
sium, maintaining a fractional reabsorption rate of 80% of the
delivered load. However, when plasma magnesium was elevat-
ed with intravenous infusions of magnesium salts, the ability of
the loop of Henle to reabsorb progressively more magnesium
was sharply blunted, presumably because magnesium reabsorp-
tion was retarded at the basolateral border of the thick ascend-
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ing limb cells by the elevated peritubular capillary magnesium
levels. Also, as plasma magnesium was raised, calcium reab-
sorption by the ioop of Henle was progressively reduced;
sodium reabsorption remained at relatively normal levels until
magnesium concentration was elevated to more than 10 mEq/
liter. The loop of Henle thus has a marked intrinsic ability to
reabsorb progressively more concentrated solutions of magne-
sium. Its reabsorptive capacity decreases, however, as plasma
magnesium rises, allowing more and more magnesium to escape
into the urine. In fact, most of the additional magnesium
delivered to the early distal tubule is excreted in the urine.
The microperfusion experiments I just described were com-
pared with similar free-flow micropuncture experiments per-
formed earlier in the dog. Massry, Coburn, and Kleeman have
described a maximal renal reabsorption rate (Tm) for magne-
sium as plasma magnesium is progressively elevated [9]. The
micropuncture experiments suggest that this apparent Tm was a
fortuitous occurrence. When the plasma magnesium level rose,
proximal reabsorption of magnesium continued to increase, but
magnesium reabsorption in the loop of Henle rose initially but
fell to zero at the highest plasma magnesium levels. The sum of
rising magnesium reabsorption in the proximal tubule and
falling magnesium reabsorption in the loop of Henle yielded a
leveling off of magnesium reabsorption with increasing plasma
magnesium, that is, an apparent Tm. Although fortuitous, this
apparent Tm relationship is useful in assessing overall renal
magnesium handling.
Micropuncture studies of the distal convoluted tubule indi-
cate a limited reabsorptive capacity for magnesium [4, 6, 81. As
the load of magnesium delivered to the distal tubule is in-
creased, the amount of magnesium reabsorbed initially in-
creases but, because of saturation of the reabsorptive system,
any further increase in load is excreted in the urine. The total
magnesium reabsorbed in the distal convoluted tubule is less
than 5% of that filtered. Studies of magnesium reabsorption in
the cortical collecting tubules and collecting ducts indicate that
little magnesium is reabsorbed at these sites. There may be
some nephron heterogeneity, however, and deep nephrons
might contribute more to urinary magnesium excretion.
In conclusion, the principal sites of normal tubular magne-
sium reabsorption in the nephron are the proximal tubule and
the loop of Henle, with the major site being the thick ascending
limb. Major factors affecting renal magnesium excretion are
summarized in Table 1.
The renal response to hvpomagnesemia and
magnesium deficiency
Although hypomagnesemia does not necessarily reflect cellu-
lar magnesium depletion, it usually indicates a certain amount
of magnesium deficiency [10]. When hypomagnesemia occurs,
the filtered load of magnesium progressively declines with the
fall in serum magnesium concentration. Using micropuncture
techniques, we studied severe magnesium depletion in a rat
model and found that the magnesium concentration in the
proximal tubule rose in an identical fashion to that occurring
under normal circumstances [11]. Because the luminal magne-
sium concentration is diminished, however, absolute reabsorp-
tion of magnesium is greatly reduced even though the fractional
magnesium reabsorption remains at 25% to 30% in the proximal
tubule. Our studies of the loop of Henle in magnesium-depleted
rats indicate that magnesium reabsorption was more complete
in the loop of Henle than under normal circumstances. Magne-
sium concentrations in the early distal tubule fluid were ex-
tremely low (approximately TF/UF Mg 0.4) and overall reab-
sorption at this point in the nephron was over 95% of that
filtered. Thus the loop of Henle was the site in the nephron
where the major additional conservation of magnesium took
place. In this rat model of magnesium depletion, in which 30%
of body magnesium was lost and serum magnesium was dimin-
ished by 50%, fractional excretion of magnesium was reduced
from a normal in the rat of about 15% to approximately 3%.
When the plasma magnesium was rapidly elevated with intrave-
nous magnesium infusions, plasma magnesium rose promptly
and the kidney rapidly excreted large amounts of the infused
magnesium. The data suggested, in fact, that there was some
delay in the ability of the loop of Henle to reabsorb magnesium
as avidly as one might expect, and this finding might reflect a
mild cellular defect because of the magnesium depletion.
The renal response to hypermagnesemia
I already have alluded to some of the kidney's responses to
hypermagnesemia. In induced hypermagnesemia, fractional
magnesium reabsorption is reduced modestly in the proximal
tubule because of the modest inhibitory effect of elevated
plasma magnesium on net sodium and water reabsorption. The
major decrease in magnesium reabsorption takes place in the
loop of Henle, however. In fact, if plasma magnesium is raised
enough, magnesium reabsorption in the loop of Henle can
approach zero, as I noted earlier. Our experimental data
indicate that the effect of elevated plasma magnesium is on the
basolateral side of the cell; raising magnesium concentration on
the luminal side alone does not reduce magnesium reabsorp-
tion. The greatly increased load of magnesium delivered to the
distal nephron exceeds the transport capability of the distal
nephron segments, and most of the magnesium rejected in the
loop of Henle is excreted into the urine. Some data suggest that
magnesium may be added to the descending limb of the deep
nephrons in hypermagnesemia and perhaps to the collecting
duct system, but on balance the data are inconclusive. There is
no question that the major site of reduced magnesium reabsorp-
tion in is the thick ascending limb of Henle's
loop.
Interrelationship of magnesium and calcium reabsorption
Hypercalcemia causes not only hypercalciuria but also hy-
permagnesiuria. As I mentioned, hypermagnesemia also leads
to marked hypercalciuria as well as hypermagnesiuria. Our
microperfusion data in the rat point to the loop of Henle as the
site where the competition of calcium and magnesium for
Table 1. Major factors controlling magnesium excretion
GFR and filtered load
Extracellular fluid volume
Hypermagnesemia
Hypomagnesemia
Phosphate depletion
Hypercalcemia
Parathyroid hormone
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transport occurs. The cellular site probably is the basolateral
membrane even though this interaction was not confirmed in in-
vitro microperfusion studies in the rabbit [7]. We hypothesize
that there is a competitive active transport process sensitive to
the absolute concentration of calcium and magnesium in the
interstitial fluid and that this process is somewhat more sensi-
tive to magnesium than to calcium. The transport system has a
more important effect on magnesium excretion than it does on
calcium excretion. This hypothesis makes it important that one
keep in mind the effects of both plasma calcium and magnesium
concentrations whenever a maneuver is utilized that alters the
excretion of these cations. One must be sure that the derange-
ments of calcium and magnesium excretion are not due to
altered plasma calcium or magnesium levels.
The effects of hypomagnesemia and hypocalcemia on magne-
sium and calcium reabsorption in the loop of Henle have not
been studied to as great an extent as have the effects of
hypermagnesemia and hypercalcemia. Hypocalcemia may aug-
ment calcium and magnesium reabsorption, however [2, 3].
Thus, the competitive transport system for calcium and magne-
sium in the loop of Henle allows greater levels of calcium and
magnesium reabsorption when either the plasma calcium or
magnesium concentration is depressed. Patients with familial
hypocalciuric hypercalcemia also have hypermagnesemia [121,
and it is tempting to speculate that the calcium-magnesium
transport system might he less sensitive to the inhibitory action
of elevated plasma calcium and magnesium concentrations in
these interesting patients.
The effect of extracellular fluid volume on magnesium
excretion
The proximal tubule is sensitive to changes in extracellular
fluid volume, largely because of alterations in transcapillary
forces that affect the degree of sodium backflux, and hence net
sodium and water reabsorption. Magnesium reabsorption is
similarly affected by changes in extracellular volume, presum-
ably via changes in the intraluminal magnesium concentration
in turn determined by net sodium and water reabsorption. We
observed in microperfusion experiments that, as flow rate to the
loop of Henle is progressively increased, fractional magnesium
reabsorption is reduced at this site [3]. I believe that an increase
in flow rate to the loop of Henle reduces the transtubular
sodium gradient and electrical potential, which may account for
the lower fractional reabsorption, as magnesium reabsorption is
largely voltage dependent. Overall, volume expansion causes a
much greater fractional increase in urinary magnesium excre-
tion than in urinary sodium excretion.
Diuretics and magnesium excretion
Carbonic anhydrase inhibitors blunt magnesium reabsorption
in the proximal tubule, hut the extra magnesium delivered to the
loop of Henle is largely recaptured there so that virtually no
increase in urinary magnesium excretion occurs [13]. Thiazide
diuretics initially can cause a small increase in magnesium
excretion, but this usually is not sustained [141. The most potent
diuretic agents that affect magnesium excretion are the osmotic
diuretics such as mannitol and urea [15. 161 and the loop
diuretics such as furosemide and ethacrynic acid [17]. The
osmotic diuretics principally reduce magnesium reabsorption in
the loop, an effect probably related to the greatly diminished
sodium chloride and water reabsorption. Loop diuretics, such
as furosemide, markedly inhibit magnesium reabsorption, again
probably secondary to diminished sodium chloride and water
reabsorption. When fractional reabsorption rates are compared.
magnesium reabsorption is reduced relatively more than that of
calcium and calcium reabsorption more than that of sodium.
Parathyroid hornone and magnesium excretion
Parathyroid hormone is the principal hormone that affects
renal magnesium reabsorption. The latest studies suggest that
parathyroid hormone enhances tubular magnesium reabsorp-
tion and that the effect takes place in the loop of Henle and the
distal convoluted tubule; this has been most clearly shown in
the golden hamster, which is very sensitive to the action of
parathyroid hormone [18]. Following parathyroidectomy in this
species, calcium and magnesium excretion rose to 20% of the
filtered load, a change rapidly reversed by the administration of
parathyroid hormone or cyclic AMP. The effects of parathyroid
hormone on magnesium transport, however, are readily over-
come by more important factors such as hypercalcemia and
hypermagnesemia. Whether parathyroid hormone plays a role
in the normal day-to-day regulation of renal magnesium reab-
sorption is unclear.
Other factors that may influence magnesium excretion
Renal potassium wasting is a well-established accompani-
ment of hypomagnesemia and magnesium depletion. Whether
this association is due to secondary hyperaldosteronism or to
direct influences on cellular potassium metabolism is not
known, but derangements in potassium balance are commonly
noted with altered magnesium homeostasis [19].
A number of other circumstances also affect magnesium
excretion. Phosphate depletion can result in significant magne-
siuria [1, 31. Acute acidosis may increase magnesium excretion,
which can be corrected by alkali infusions [20]. A number of
hormonal agents such as thyroid hormone, calcitonin, and
vitamin D metabolites can have extrarenal influences on magne-
sium metabolism [1, 3}. Alcohol can increase magnesium excre-
tion in some instances [211. Urinary magnesium wasting is a
frequently observed consequence of the chronic use of drugs
such as cisplatin, gentamicin, and perhaps amphotericin 122,
231.
Summary o.t renal handling of magnesium
Renal magnesium transport is altered by changes in plasma
magnesium and plasma calcium and by changes in extracellular
fluid volume. Loop diuretics and osmotic diuretics can pro-
foundly reduce magnesium reabsorption. Evidence supports
the contention that parathyroid hormone can enhance magne-
sium reabsorption in the nephron. Interrelationships of hypo-
magnesemia and magnesium depletion to overall calcium and
potassium metabolism are complex but appear to be dependent
on tissue magnesium concentration.
Clinical causes of hvpon,agncsemia
I now would like to return to today's 2 patients with hypo-
magnesemia. They represent the two broad clinical mechanisms
of hypomagnesemia: defective gastrointestinal absorption of
magnesium and renal magnesium wasting. The first patient,
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who had a small-bowel bypass for obesity, illustrates one cause
of defective intestinal absorption of magnesium (Table 2). Other
gastrointestinal causes include idiopathic steatorrhea, various
diseases of the distal ileum with or without resection, biliary
fistula, and partial gastric resection. Poor gastrointestinal ab-
sorption also can occur as an isolated hereditary defect [24] or
in association with malnutrition, especially protein deficiency.
Alcoholics develop hypomagnesemia because of poor dietary
magnesium intake, but also because of increased renal magne-
sium excretion. Hypomagnesemia also can occur during pro-
longed intravenous therapy with fluids containing insufficient
magnesium.
The first patient had hypomagnesemia severe enough to
cause all the common physical signs of neuromuscular irritabil-
ity associated with hypomagnesemia and hypocalcemia. She
had associated mild hypokalemia. Treatment with magnesium
sulfate rapidly corrected the low serum magnesium, and her
serum calcium level rose spontaneously without administration
of additional calcium. The latter effect may be the result of
increased secretion of parathyroid hormone or increased cellu-
lar sensitivity to parathyroid hormone following magnesium
repletion [25]. We should note that the measured parathyroid
hormone levels were still in the normal range in the presence of
the severe hypocalcemia, suggesting impairment of PTH secre-
tion. Initially the urine magnesium was exceedingly low, re-
flecting intense renal conservation of magnesium. The fraction-
al excretion of magnesium rose sharply when supplemental
magnesium was given, however, indicating inefficient renal
retention of needed magnesium.
The second patient with hypomagnesemia represents an
instance of renal magnesium wasting. As indicated in Table 3,
there are many causes of renal magnesium wasting. These
include a primary defect in renal magnesium reabsorption
(which may be an inherited disorder [261), magnesium wasting
associated with the osmotic diuresis of diabetic ketoacidosis,
and a variety of other clinical disorders such as Bartter's
syndrome. Magnesium wasting frequently accompanies vigor-
ous diuresis such as that occurring in hypercalcemic patients
given furosemide. It also can accompany the use of certain
antimicrobial and chemotherapeutic agents such as gentamicin
[23], amphotericin B [22], and cisplatin [27]. Our second patient
is, indeed, very complicated, because the ovarian cancer was
treated with a variety of chemotherapeutic agents, including
cisplatin. She then developed a nonlymphocytic leukemia and,
because of the associated candida infections, required ampho-
tericin B therapy. The inappropriately high values for urinary
magnesium during hypomagnesemia in this patient indicated
that she had a renal magnesium-wasting disorder. The magne-
sium wasting probably resulted from the effects of cisplatin and
was aggravated by the concomitant diuretic and antimicrobial
drug therapy.
Primary renal magnesium wasting
Loop diuretics
Diabetic ketoacidosis (osmotic diuresis)
Bartter's syndrome
Hyperaldosteronism
Syndrome of inappropriate ADH secretion
Alcoholism
Hypercalciuria or salt-wasting states
Amphotericin toxicity
Aminoglycosides (gentamicin)
Cisplatin
Several groups have reported magnesium wasting in patients
receiving cisplatin. Schilsky and Anderson in 1979 found hypo-
magnesemia in 23 of 44 patients receiving cisplatin [27]. Cispla-
tin can cause other types of renal damage such as acute tubular
necrosis. Amphotericin B is thought to cause mild hypomagne-
semia. There is no question that the patient had chronic tubular
damage in the segments responsible for magnesium reabsorp-
tion, as she continued to have low serum magnesium levels
because of a renal magnesium leak. The site of this defective
magnesium reabsorption is completely conjectural at this time,
but one could postulate that the defect resides in the thick
ascending limb, where the principal amount of magnesium
reabsorption normally takes place. However, if the proximal
tubular damage were severe enough and if the delivery of
filtrate to the loop of Henle were sufficiently high, then the
magnesium absorptive capacity of the loop of Henle could be
overwhelmed. This patient also had hypokalemia and hypocal-
cemia, which are not readily explained. The interrelationship of
magnesium and calcium is similar to that in the first patient; that
is, there may be both resistance to the action of parathyroid
hormone and impairment of parathyroid hormone secretion
[25]. The magnitude of the potassium losses seems too great to
ascribe to the effects of hypomagnesemia alone and might
reflect additional toxicity due to amphotericin B as well as
cisplatin. Whether other aspects of the patient's condition, such
as her repetitive attacks of hemolysis, are related to hypomag-
nesemia remains unanswered.
Questions and answers
DR. DAVID PARKINSON (Hematology/Oncology Division,
NEMC): Dr. Dirks, other heavy metals such as selenium and
gallium are now in the first phase of testing as potential
antineoplastic agents. Would you expect that such heavy met-
als, which are known to be nephrotoxic, also might affect
magnesium transport?
DR. DIRKS: I know of no data indicating that any of these
agents affect magnesium transport in experimental animals or in
humans in the same manner as cisplatin, although certainly
such data would be important.
DR. ROBERT SCHWARTZ (Chief Hematology/Oncology Divi-
sion, NEMC): Is it likely that the administration of aminoglyco-
sides contributed to the renal problems in the second patient
presented?
DR. DIRKS: I believe that the major cause of the magnesium
wasting was cisplatin administration, although other factors
such as aminoglycosides also might have played a role. There
Table 2. Gastrointestinal causes of hypomagnesemia
Malabsorption syndromes
Protein calorie malnutrition
Alcoholism
Prolonged gastrointestinal suction
Prolonged intravenous therapy
Table 3. Renal magnesium wasting
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are reports of hypomagnesernia occLirring with gentamicin
alone [231.
DR. SCHWARTZ: Dr. Parkinson. do you think it appropriate to
use tobrarnycin in patients who are receiving cisplatin?
DR. PARKINSON: No, 1 don't think that aminoglycosides and
cisplatin should be used together. Cisplatin and gentamicin in
combination can result in severe nephrotoxicity [28]. Because
cisplatin can persist in the kidney For as long as one year. it
might even he prudent to avoid the use of aminoglycosides in
patients who received cisplatin in the recent past if possible. I
am not aware, however, of specific information concerning the
interaction of tobramycin with cisplatin.
DR. JEROME P. KASSiRER: Do we know the precise cause of
magnesium wasting in patients given aminoglycosides? Where
is the specific tubular defect of magnesium reabsorption?
DR. DiRKS: Available studies do not provide an exact answer
to this question. We do know, however, that the renal toxicity
of aminoglycosides is directed primarily at the proximal tubule.
One might imagine that reduced magnesium reabsorption in the
proximal tubule would increase magnesium delivery to the loop
of Henle, and that this increase would exceed the reabsorptive
capacity of the loop, thereby resulting in magnesiuria. Alterna-
tively, defective reabsorption could occur within the loop of
Henle.
DR. KASSiRER: Would you comment on the mechanisms of
potassium wasting in magnesium deficiency?
DR. DIRKS: Hypokaleniia and potassium depletion are com-
monly thought to accompany magnesium deficiency. The initial
studies of Welt, in which hypomagnesemia and magnesium
depletion were produced in rats by dietary magnesium depriva-
tion, showed that potassium depletion was a frequent accompa-
niment [291. The mechanism responsible for the hypokalemia
and potassium depletion is not understood and frequently has
been attributed to defective potassium handling by the kidney.
In our own studies in magnesium-depleted rats, we did not find
renal potassium wasting. Micropuncture studies of the distal
tubule confirmed that potassium transport was essentially nor-
mal. Thus, the potassium depletion that occurs with magnesium
deficiency is not due to altered renal potassium handling hut
might reflect defective magnesium-potassium transport at the
cellular level.
DR. JOHN T. HARRINGTON: Is it possible that the "self-
depression" of magnesium absorption by the nephron in hyper-
magnesemic experimental animals is due to elevated magne-
sium levels in the peritubular capillaries? Could such high
concentrations have a direct ellect on magnesium transport
across the thick ascending limb?
DR. DIRKS: Our studies suggest that hypermagnesemia in the
perituhular capillaries, and therefore in the interstitial fluid, is
indeed responsible lbr the "self-depression" of magnesium
transport. In our in-vitro mieroperfusion studies of the loop and
our free-flow studies of proximal and early distal tubule magne-
sium reabsorption, progressive elevations in plasma magnesium
caused a progressive decline in magnesium reabsorption within
the loop of Henle. We postulate that a high magnesium level can
inhibit magnesium reabsorption across the contralumina] aspect
of the tubular cell. The recent in-vitro mieroperfusion experi-
ments of Shareghi and Agus confirm this finding: raising the
niagnesiurn concentration in the fluid in which the tubule was
immersed reduced magnesium reabsorption 171. Elevating mag-
nesium concentration in the lumen has the opposite effect: it
increases reabsorption.
DR. HARRINGTON: What is the evidence for magnesium
secretion in the nephron?
DR. DIRKs: Mieropuneture studies pert'ormed by LeOrimel-
lee and colleagues [30] as well as by us revealed instances in
which more magnesium appeared in the urine than was present
in the late distal tubule 131]. This finding suggested that there
was magnesium secretion somewhere in the collecting ducts.
These observations also could he explained, of course. by
nephron heterogeneity. Further, puncture of the cortical col-
lecting tubules by Brunette and colleagues did not demonstrate
magnesium secretion [321. Our own recent micropuncture stud-
ies detected little evidence of magnesium backflux into the
lumen. The general conclusion has been that magnesium secre-
tion, if it occurs, is of minor importance in the physiologic
regulation of magnesium excretion. It is better to think of the
nephron as able to reduce its magnesium reabsorption almost to
zero when reqtnred. However, if the clearance studies reported
in the literature are taken at face value, the possibility of
magnesium secretion remains. It will he important to test
individual nephron segments by in-vitro perfusion experiments
in the presence of a high bath magnesium concentration to
demonstrate more unequivocally whether magnesium secretion
occurs.
DR. DAVID CAHAN (Chief, Nephrologv Division, Faulkner
Hospital, Boston): Dr. Dirks, are there any important interrela-
tionships between magnesium and phosphate metabolism?
DR. DIRKs: Magnesiuria can occur during phosphate deple-
tion. Coburn and Massry observed this phenomenon in their
studies of phosphate depletion in the dog [331. In our micro-
puncture studies in the dog, magnesium excretion appeared
normal during phosphate depletion hut decreased significantly
when phosphate stores were repleted and when parathyroid
hormone levels were restored to normal [34].
DR. NICOIAOS E. MADIA5: Could you comment on the
changes in renal magnesium handling in patients who are being
treated chronically with thiazides?
DR. DIRKS: Magnesium excretion tends to remain normal or
increase slightly immediately after thiazide administration [17].
Mild magnesiuria can occur in patients being treated chronically
with thiazides 1351. In our mieropuncture experiments in the
hamster, thiazides caused no immediate change in magnesium
reabsorption even though the expected natriuretie and calcium-
retaining effects of the agent in the distal tubule could be
demonstrated 114]. The reason for the persistent magnesiuria in
some patients who chronically receive thiazides is not clear, but
it might be related to an effect of thiazides on distal magnesium
transport too small to he detected during acute experiments, or
to increased delivery to distal sites of magnesium escaping loop
reabsorption.
DR. HARRINOTON: Dr. Dirks, magnesium-depleted rats be-
come hypercalcemic. not hypocalcemic as do magnesium-
depleted humans. Could you comment on the reasons for this
species difference?
DR. DIRK5: As I discussed, the hypoealceniia that occurs in
hypomagnesemia in humans is a complex affair involving defec-
tive PTH secretion. insensitivity of the bone to PTH, and
defective exchange between the extracellular fluid and the
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bone. These mechanisms have not been studied in detail in the
rat and might not be as impaired.
DR. MADIAS: Could you please comment further on the effect
of hypomagnesemia on PTH secretion. Some experimental
evidence suggests that this effect might be influenced by the
degree of decline in magnesium concentration.
DR. DIRKS: This appears to be true, as initially hypomagnese-
mia increases PTH secretion, but more profound hypomagnese-
mia reduces PTH secretion. Correction of plasma magnesium is
often necessary to correct blunted PTH secretion and hypocal-
cemia, as in the first patient presented 1361.
DR. CAHAN: What happens when patients with familial
hypocalciuric hypercalcemia are given magnesium?
DR. DIRKs: There are not enough observations of this type to
answer your question with certainty. It would appear that
magnesium infusion in such patients results in more magnesium
retention at any plasma level of magnesium. Of course, when
plasma magnesium concentration is raised sufficiently, magne-
siuria occurs.
DR. MADIAS: Does hypermagnesemia or hypomagnesemia
exert any important influence on PTH secretion and the level of
serum calcium in patients with chronic renal insufficiency?
DR. DIRKs: Hypermagnesemia probably does not exert an
important effect on PTH secretion in patients with renal insuffi-
ciency; however, hypocalcemia secondary to hypomagnesemia
has been observed in patients with renal failure as well as in
patients with normal renal function.
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